Ruth Wester

1.0k total citations
14 papers, 299 citations indexed

About

Ruth Wester is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ruth Wester has authored 14 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Ruth Wester's work include Multiple Myeloma Research and Treatments (10 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (4 papers). Ruth Wester is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (4 papers). Ruth Wester collaborates with scholars based in Netherlands, Italy and United States. Ruth Wester's co-authors include Neil A. Hanley, E. McGee, John McCarthy, William E. Rainey, Chiravudh Sawetawan, Ian M. Bird, J. Ian Mason, Joost P.H. Drenth, Gregory T. Everson and Kim McFann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Ruth Wester

10 papers receiving 296 citations

Peers

Countries citing papers authored by Ruth Wester

Since Specialization

Citations

This map shows the geographic impact of Ruth Wester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Wester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Wester more than expected).

Fields of papers citing papers by Ruth Wester

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Wester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Wester. The network helps show where Ruth Wester may publish in the future.

Co-authorship network of co-authors of Ruth Wester

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Wester. A scholar is included among the top collaborators of Ruth Wester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Wester. Ruth Wester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis 2025 ·Blood ·(unknown), Ruth Wester, Inger S. Nijhof, (unknown), (unknown), (unknown), (unknown)	0
2	Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab 2025 ·Bone Marrow Transplantation ·(unknown), (unknown), Nik Veldhoen, (unknown), Bronno van der Holt, (unknown), Ruth Wester, Emma de Pater, Paula F. Ypma, Annoek E. C. Broers, Pieter Sonneveld, Annemiek Broijl	0
3	Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma 2024 ·Blood ·Annemiek Broijl, Fredrik Schjesvold, (unknown), Djamila E. Issa, Sonja Zweegman, Kon‐Siong G. Jie, Mario Boccadoro, Roman Hájek, Bronno van der Holt, Ruth Wester, Pieter Sonneveld	0
4	Treatment emergent peripheral neuropathy in the CASSIOPEIA trial 2022 ·Haematologica ·(unknown), Philippe Moreau, Bronno van der Holt, Jérôme Lambert, Mark van Duin, Ruth Wester, Joost L.M. Jongen, Pieter A. van Doorn, (unknown), (unknown), Olivier Fitoussi, Michel Delforge, (unknown), Odile Luycx, Tom Cupedo, Niels W.C.J. van de Donk, Sonja Zweegman, Jessica Vermeulen, Pieter Sonneveld, Annemiek Broijl	2
5	Peripheral Neuropathy in the Cassiopeia Study 2020 ·Blood ·(unknown), Bronno van der Holt, Mark van Duin, Ruth Wester, Tom Cupedo, Philippe Moreau, Jessica Vermeulen, Annemiek Broyl, Pieter Sonneveld	1
6	Carfilzomib Combined With Thalidomide and Low‐dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial 2020 ·HemaSphere ·Ruth Wester, Sonja Zweegman, Bronno van der Holt, Marie José Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, (unknown), Okke de Weerdt, Monique C. Minnema, Sarah Lonergan, Antonio Palumbo, Annemiek Broijl, Pieter Sonneveld	0
7	Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial 2019 ·Haematologica ·Ruth Wester, Bronno van der Holt, (unknown), Sonja Zweegman, Marie José Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerdt, Monique C. Minnema, Sarah Lonergan, Antonio Palumbo, Henk M. Lokhorst, Annemiek Broijl, Pieter Sonneveld	22
8	Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS 2017 ·Blood ·Ruth Wester, King H. Lam, Mark van Duin, Suzana S. Couto, Yan Ren, Maria Wang, Bronno van der Holt, Berna Beverloo, Heleen Visser-Wisselaar, Alex L. Nigg, (unknown), Anjan Thakurta, Annemiek Broyl, Sonja Zweegman, Pieter Sonneveld	1
9	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial 2016 ·Blood ·Ruth Wester, Bronno van der Holt, (unknown), Mark van Duin, Sonja Zweegman, Marie José Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerdt, Monique C. Minnema, Sarah Lonergan, Antonio Palumbo, Henk M. Lokhorst, Annemiek Broijl, Pieter Sonneveld	9
10	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). 2016 ·Journal of Clinical Oncology ·Michèle Cavo, Antonio Palumbo, Sonja Zweegman, Meletios Α. Dimopoulos, Roman Hájek, Lucia Pantani, Meral Beksaç, Ruth Wester, Hans Erik Johnsen, Ulf‐Henrik Mellqvist, Maria Teresa Petrucci, Christoph Driessen, Francesco Di Raimondo, Rossella Troia, Annalisa Pezzi, Bronno van der Holt, Ka Lung Wu, H Ludwig, Francesca Gay, Pieter Sonneveld	47
11	Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease 2007 ·Liver International ·(unknown), Ruth Wester, Robert W. Schrier, Kim McFann, R. Brian Doctor, Joost P.H. Drenth, Gregory T. Everson	80
12	Parathyroid hormone & parathyroid hormone-related peptide stimulate aldosterone production in the human adrenocortical tumor cell line, NCI-H295 [NCIH295] 1993 ·Neil A. Hanley, Ruth Wester, Bruce R. Carr, W E Rainey	5
13	Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. 1993 ·The Journal of Clinical Endocrinology & Metabolism ·William E. Rainey, Ian M. Bird, Chiravudh Sawetawan, Neil A. Hanley, John McCarthy, E. McGee, Ruth Wester, J. Ian Mason	131
14	A study of depression in alcoholic patients. 1979 ·PubMed ·Ruth Wester, (unknown), Ronald E. Kleinman, Donald M. Gallant, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact